Table 3 Late complications of adults who underwent Ross or mAVR Table 3 Late complications of adults who underwent Ross or mAVR Table 3 Late complications of adults who underwent Ross or mAVR Table 3 Late complications of adults who underwent Ross or mAVR
Any Complications at Follow-Up Any Complications at Follow-Up Any Complications at Follow-Up
Estimates for Ross 95% CI p-value
Time-to-follow-up (y)a -0.64 -3.28, 1.99 0.62
New York Heart Association functional classificationb 0.36 0.09, 1.44 0.15
Echocardiograma
Left ventricular ejection fraction (%) 4.65 -3.02, 12.33 0.24
Peak aortic valve gradient (mm Hg) -23.00 -33.90, -12.10 < 0.01
Mean aortic valve gradient (mm Hg) -12.49 -19.17, -5.80 < 0.01
Peak pulmonic valve gradient (mm Hg) 2.48 -1.85, 6.81 0.26
Mean pulmonic valve gradient (mm Hg) 3.29 -1.23, 7.80 0.15
Sinus of Valsalva (mm) 4.31 -0.30, 8.93 0.07
Ascending aorta (mm) -3.39 -14.52, 7.74 0.55
Late complicationsbc
Bleeding 0.03 0, 0.24 < 0.01
Stroke 0.06 0.00, 0.51 < 0.01
Endocarditis 0.17 0, 1.66 0.13
Arrhythmia 1.63 0.34, 9.01 0.73
Aortic root dilatation 4.10 0.99, 18.96 0.052
Ascending aortic dilatation 6.37 0.70, 315.12 0.13
Among patients who had any complication at follow-up, variables expressed above as amatched 𝛽-coefficients or bmatched odds ratio. cexact weight logistical regression. Among patients who had any complication at follow-up, variables expressed above as amatched 𝛽-coefficients or bmatched odds ratio. cexact weight logistical regression. Among patients who had any complication at follow-up, variables expressed above as amatched 𝛽-coefficients or bmatched odds ratio. cexact weight logistical regression. Among patients who had any complication at follow-up, variables expressed above as amatched 𝛽-coefficients or bmatched odds ratio. cexact weight logistical regression.